ANX, ADVENTRX Pharmaceuticals (AMEX: ANX) has recently reported the results from a preclinical study affirming the bioequivalence and comparable toxicity of ANX-514 and Taxotere. ADVENTRX's partner for the ANX-514 project, Shin Poong Pharmaceuticals in South Korea conducted the study and data analysis.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
ANX-514 is a novel emulsion formulation of docetaxel, a chemotherapy drug formulation of which is marketed under the brand name Taxotere. ANX-415 is produced without polysorbate 80 or other detergents and is expected to reduce the severity and or incidence of the hypersensitivity reactions which are often associated with Taxotere.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
